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WHOSE CELL LINE IS IT ANYWAY? INTELLECTUAL
PROPERTY IMPLICATIONS OF NEW JERSEY’S POLICY ON
STEM CELL RESEARCH
Gary R. Tulp ∗
I.

INTRODUCTION

Human stem cells, the most basic cells of the human body, have
the unique ability to develop into more sophisticated cells and to re1
pair or replenish defective cells. Scientific research on human stem
cells bears enormous potential because “when a stem cell divides,
each new cell has the potential to either remain a stem cell or become another type of cell with a more specialized function, such as a
2
muscle cell, a red blood cell, or a brain cell.” Indeed, in 2000, the
federal government announced for the first time its position that “the
potential medical benefits of human . . . stem cell technology are
compelling and worthy of pursuit in accordance with appropriate
3
ethical standards.” Similarly, despite the relative uncertainty regarding the potential advances derived from stem cell research, significant data indicate that research advocates’ initial enthusiasm is justi4
fied.
For purposes more relevant to this Comment, New Jersey’s lawmakers have declared that “human stem cell research offers immense
∗

J.D. 2008, Seton Hall University School of Law; B.A., Communication Studies,
2002, The College of New Jersey.
1
NAT’L INSTS. OF HEALTH, U.S. DEP’T OF HEALTH & HUM. SERVS., STEM CELL
INFORMATION: STEM CELL BASICS 1 (2006), http://stemcells.nih.gov/staticresources/
info/basics/StemCellBasics.pdf.
2
Id.
3
Press Release, Nat’l Insts. of Health, NIH Publishes Final Guidelines for Stem
Cell Research (Aug. 23, 2000), available at http://www.nih.gov/news/pr/aug2000/
od-23.htm [hereinafter NIH Publishes Final Guidelines].
4
AUDREY R. CHAPMAN ET AL., STEM CELL RESEARCH AND APPLICATIONS MONITORING
THE FRONTIERS OF BIOMEDICAL RESEARCH 1 (1999), http://www.aaas.org/spp/dspp/
sfrl/projects/stem/report.pdf. This report is “endorsed by the Board of Directors of
the American Association for the Advancement of Science and by the Institute for
Civil Society as a contribution to the public discussion of issues related to stem cell
research and applications.” Id.
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promise for developing new medical therapies for . . . debilitating
diseases and a critical means to explore fundamental questions of biology. Stem cell research could lead to unprecedented treatments
and potential cures for Alzheimer’s disease, cancer, diabetes, Parkin5
son’s disease and other diseases.” To that end, in January 2004, New
Jersey became the second state (after California) to statutorily author6
ize stem cell research. In December 2005, New Jersey became the
first state to publicly fund research of human embryonic cells, including research on certain cell lines which is ineligible for federal fund7
ing. The state has committed $8.5 million in public funds to finance
8
the research conducted at the Stem Cell Institute of New Jersey.
Manifested by these legislative assurances, an underlying objective of New Jersey’s pioneer stem cell policy is also “[t]o encourage
and enable the state’s renowned research and life sciences communi9
ties to develop quality, innovative treatments for patients.” Thus, although New Jersey’s policy of encouraging stem cell innovation relies
on these private entities, this Comment suggests that existing and
pending New Jersey legislation and policy do not adequately clarify to
whom the intellectual property rights belong in the case of publicly
funded, but privately innovated, stem cell research. This lack of clarity may prove to be a disincentive that hinders the development of
the anticipated breakthroughs expected of stem cell research.
Part II of this Comment explains the science involved in stem
cell research, then traces federal and state policies concerning that
research, and concludes with a detailed description of New Jersey’s
stem cell policy and legislation. Part III then explains the intellectual
property issues that arise in the context of publicly funded stem cell
research programs and how these problems are likely to arise under
New Jersey’s scheme. Finally, Part IV evaluates legislative solutions
designed to remedy similar problems in other arenas of publicly
5

N.J. STAT. ANN. § 26:2Z-1(c) (West 2006).
CAL. HEALTH & SAFETY CODE § 125300 (West 2004) (authorizing stem cell research); see also 2003 N.J. Laws 203 (codified at N.J. STAT. ANN. § 26:2Z-1 (West
2004)); see also Ella Detrizio & Chris Brennan, The New Jersey Stem Cell Research Law, 3
N.J. LIFESCITECH 8–9 (2004).
7
State of New Jersey Commission on Science & Technology, Stem Cell, http:
//www.state.nj.us/scitech/stemcell/ (last visited Feb. 6, 2008) (discussing the Commission’s awarding of grants totaling $5 million to seventeen research teams) [hereinafter N.J. Sci. & Tech.].
8
Stem Cell Institute of New Jersey, About the Institute, http://www2.umdnj.
edu/scinjweb/about/index.htm (last visited Feb. 18, 2008) (“The mission of the Institute is to carry out research, training, and clinical studies on the application of
stem cells to the treatment and cure of human disease.”).
9
Id.
6
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funded innovation, ultimately contending that New Jersey has several
options at its disposal to alleviate potential intellectual property disputes that would otherwise hinder the development of stem cell research.
II. BACKGROUND OF THE SCIENCE BEHIND
STEM CELL RESEARCH, FEDERAL POLICY, AND STATE POLICY
A. Scientific and Technological Understanding
The advent of human embryonic stem cell research can be
traced to 1998, when Drs. James Thompson and John Gearhart each
isolated and cultured human embryonic stem cells for research pur10
poses. Understanding the science behind stem cell research begins
with the concept that “[t]he stem cell is the alpha cell of all cells. Yet
11
the stem cell is the most basic cell in the human body.” Researchers
acquire stem cells from embryos that were fertilized in an in vitro fertilization clinic and subsequently donated with the informed consent
12
“All stem cells—regardless of their source—have
of the donor.
three general properties: they are capable of dividing and renewing
themselves for long periods; they are unspecialized; and they can give
13
rise to specialized cell types.” As they are unspecialized, stem cells
cannot themselves perform specific cellular functions, such as pumping blood or causing bodily movement, but they can bring about specialized cells, such as blood, nerve, or cardiac muscle cells, through a
14
process known as differentiation.
Scientists classify stem cells as belonging to one of three distinct
15
types: totipotent, pluripotent, and multipotent.
While both the
totipotent and pluripotent cells have the potential to develop into
10

Heather L. Fowler, Note, Misapplied Ethical Considerations: U.S. Federal Stem Cell
Mandates Lack Global Focus and Market Foresight, 36 CORNELL INT’L L.J. 521, 523 (2004).
It should be noted that Drs. Thompson and Gearhart, although employed by the
University of Wisconsin and Johns Hopkins University, respectively, conducted this
research in their individual and private capacities. Id.
11
Carly Goldstein, Note, Dipping into Uncle Sam’s Pockets: Federal Funding of Stem
Cell Research: Is It Legal?, 11 B.U. PUB. INT. L.J. 229, 231 (2002) (citing NAT’L INSTS. OF
HEALTH, STEM CELLS: A PRIMER (2000)). That is, although the stem cell is the most
basic of all human cells, it is considered the alpha cell because of its dominant effect
on the future development of the body. Id.
12
NAT’L INSTS. OF HEALTH, supra note 1, at 6.
13
Id. at 4. “Unspecialized” cells are cells that lack tissue-specific structures that
enable them to execute any specialized functions. Id. “Specialized” cells, to the contrary, are structured to perform specific bodily functions. Id.
14
Id.
15
Goldstein, supra note 11 (discussing CHAPMAN ET AL., supra note 4).
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16

any cellular structure within the human body, only the totipotent
stem cell—formed at the moment when the sperm fertilizes the
17
egg—can develop into a fully functional organism. Conversely, as
an already specialized stem cell, the ultimate development of the
multipotent stem cell—cultivated from adult stem cells without much
controversy—is limited to the certain tissue which it already com18
prises.
As such, scientists believe that advances in stem cell research will
lead to several medical breakthroughs because researchers can tap
the substantial potential of stem cells prior to their ultimately limiting
19
transformation into a specific body part. These anticipated breakthroughs include understanding the complexities of human development, safer and more precise testing of new and experimental
drugs, and, perhaps most importantly, cell-based therapies. Such
therapies include the creation of replacement tissues, renewable
sources for organ transplants, and treatment of diseases and conditions, including Alzheimer’s disease, Parkinson’s disease, diabetes,
20
spinal cord injury, and many more.
B. Federal Policy on Stem Cell Research
Since the inception of stem cell research and technology, poli21
cymakers have wrestled with numerous ethical and moral concerns.
Most fundamentally, the ethical dilemma surrounding human embryonic stem cell research is rooted in the issue of whether the cells
22
are characterized as embryos or merely specialized body tissue. In
order to make the taxing determination of whether stem cells are
more analogous to somatic tissue rather than human embryos depends largely on determining the potentiality of a cell—a cell’s po23
tential to become a person. Because technically any cell in the hu16

Id. at 231–32.
Id. at 232.
18
Id.
19
Joanna K. Sax, The States “Race” with the Federal Government for Stem Cell Research,
15 ANNALS HEALTH L. 1, 5 (2006); see supra note 14 and accompanying text.
20
NAT’L INSTS. OF HEALTH, supra note 1, at 15.
21
See generally CHAPMAN ET AL., supra note 4.
22
Id. at 11 (“Although the answer to this question will be less important to those
who believe that the early embryo has little or no moral status, it will shape the views
of those who regard the embryo as significantly protectable.”). This distinction is so
crucial to the ethical determination because, depending on which perspective one
subscribes to, the use of stem cells will either be deemed destruction of life or, less
profoundly, morally acceptable scientific research—a debate that evokes many of the
concerns associated with the abortion debate. See id.
23
Id.
17
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man body could become a person because of breakthroughs in cloning, proponents of stem cell research have circumvented this possible
obstacle by focusing their arguments on the natural propensity of
24
embryonic stem cells to become a person. That is, “embryos have a
natural potentiality to become a person in that the natural develop25
ment of an embryo, unlike tissue, is to become a human being.”
Thus, advocates of stem cell research liken stem cells to tissue and
avoid the moral dilemmas traditionally associated with issues such as
26
abortion or mammalian cloning.
With these ethical concerns constantly at the forefront of the
public discussion of stem cell research, policy regarding this technol27
ogy has by and large remained conservative.
President Ronald
Reagan prohibited federal funding of stem cell research through a
28
moratorium that lasted throughout the 1980s. President Reagan rationalized his decision with the theory that embryonic and fetal research would foment abortion and render taxpayers complicit in
29
President George H.W. Bush precausing the death of fetuses.
served the moratorium, maintaining “the pro-life view that any experimentation on a fetus or embryo is equivalent to experimentation
30
on a human being.”
However, the tide began to shift in 1993 when, on his first day in
office, President Bill Clinton lifted the existing moratorium that had
31
prohibited fetal tissue research for the past decade.
Effectively,
President Clinton’s executive order provided the impetus for federal
32
Shortly thereafter, the
funding of embryonic and fetal research.
National Institutes of Health (NIH) Embryo Research Panel recom33
mended federal funding of embryo research.
24

See id. at 11–12.
Id. at 11.
26
Id.
27
See Goldstein, supra note 11, at 237–42; see also Fowler, supra note 10, at 523–25,
538–43 (providing a more detailed account of the Clinton and G.W. Bush administrations’ stem cell policies).
28
Nelle S. Paegel, Use of Stem Cells in Biotechnological Research, 22 WHITTIER L. REV.
1183, 1199 (2001).
29
Id.
30
Scott Davison, Influencing NIH Policy over Embryonic Stem-Cell Research: An Administrative Tug-of-War Between Congress and the President, 22 J. NAT’L ASS’N ADMIN. L.
JUDGES 405, 410 (2002).
31
Memorandum on Fetal Tissue Transplantation Research, 29 WEEKLY COMP.
PRES. DOC. 87 (Jan. 22, 1993); see also Debra Rosenberg & Martha Brant, Taking Aim
at Abortion, NEWSWEEK, Feb. 5, 2001, at 27.
32
Davison, supra note 30, at 410.
33
Eric Juengst & Michael Fossel, The Ethics of Embryonic Stem Cells—Now and Forever, Cells Without End, 284 JAMA 3180, 3182 (2000); see also Marjorie Shaffer, NIH
25
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Accordingly, on October 3, 1995, President Clinton created the
National Bioethics Advisory Commission (NBAC), a diverse panel of
scientists and policymakers, and charged it with investigating the con34
troversial issues surrounding stem cell research.
Ultimately, the
NBAC made broad recommendations to permit federal funding of
35
embryonic stem cell research. The essence of these recommendations was that the federal government should, under appropriate
ethical standards, fund research using cells excised from existing cadaveric fetal tissue and research using cells that would otherwise be
discarded after infertility treatments, but should not fund research
using cells from embryos that were created (either by in vitro fertiliza36
tion or somatic cell nuclear transfer) solely for research purposes.
In 1996, Congress limited the scope of federal funding used to
support stem cell research with the Dickey Amendment, which is a
37
rider to appropriations bills passed every year since its inception.
Through this enactment, Congress banned federal funding of:
(1) [T]he creation of a human embryo or embryos for research
purposes; or (2) research in which a human embryo or embryos
are destroyed, discarded, or knowingly subjected to risk of injury
or death greater than that allowed for research on fetuses in
utero.
. . . (b) For purposes of this section, the term “human embryo or
embryos” includes any organism, not protected as a human subject under [45 C.F.R. § 46] as of the date of the enactment of this
Act, that is derived by fertilization, parthenogenesis, cloning or
any other means from one or more human gametes or human
38
diploid cells.

Panel Recommends Research on Human Embryos, BIOTECHNOLOGY NEWSWATCH, Oct. 3,
1994, at 1.
34
NAT’L BIOETHICS ADVISORY COMM’N, ETHICAL ISSUES IN HUMAN STEM CELL
RESEARCH (1999), http://www.bioethics.gov/reports/past_commissions/nbac_stem
cell1.pdf.
35
Id. (“[I]n light of public testimony, expert advice, and published writings, we
have found substantial agreement among individuals with diverse perspectives that
although the human embryo and fetus deserve respect as forms of human life, the
scientific and clinical benefits of stem cell research should not be foregone.”).
36
Id. at 65–81.
37
Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, H.R. 3043 110th Cong. § 509 (2008) (illustrating the most recent
use of the language from the Dickey Amendment in the 110th Congress’s appropriations legislation); see also Roger G. Noll, California’s Stem Cell Initiative: Converting the
Legal and Policy Challenges: Designing an Effective Program of State-Sponsored Human Embryonic Stem Cell Research, 21 BERKELEY TECH. L.J. 1143, 1144 (2006).
38
H.R. 3043 § 509.
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In 1998, the Department of Health and Human Services (HHS)
declared that embryonic stem cells are incapable of developing into a
39
human being, thereby expressly removing embryonic stem cell re40
search from the purview of the 1996 Congressional ban.
Armed with this new declaration from the HHS, the NIH released new guidelines on August 23, 2000 to govern federally funded
41
stem cell research. These guidelines reflect the NIH’s new policy
that “the potential medical benefits of human pluripotent stem cell
technology are compelling and worthy of pursuit in accordance with
42
appropriate ethical standards.” In constructing this reformed policy, the NIH distinguished the 2000 Guidelines from the 1994 recommendations that were struck down by Congress. The NIH’s distinction between stem cells derived for research purposes and those
used for research purposes permit federally funded scientists to conduct research on existing stem cell lines, but not on cell lines created
43
specifically for research purposes. Thus, since the cells themselves
cannot be considered embryos, federally funded scientists are not
forbidden from conducting research on them as long as these scien44
tists comport with certain conditions prescribed by the guidelines.
39

Research Using Stem Cells: Before the S. Appropriations Subcomm. on Labor, Health
and Human Services, Education and Related Agencies, 105th Cong. (1998) (statement of
Harold Varmus, Director of National Institutes of Health, Department of Health and
Human Services), available at http://stemcells.nih.gov/policy/statements/120298
.asp; see also Kathi E. Hanna, Stem Cell Politics: Difficult Choices for the White House and
Congress, HASTINGS CENTER REP., July–Aug. 2001, at 9.
40
Extracting stem cell research from the purview of the Dickey Amendment, of
course, rests on a presumption in favor of the natural potentiality position discussed
herein. See supra notes 23–25 and accompanying text.
41
NIH Publishes Final Guidelines, supra note 3; see also Goldstein, supra note 11,
at 248–50 (explaining that the NIH guidelines do not violate the Dickey Amendment).
42
NIH Publishes Final Guidelines, supra note 3.
[Further, t]he Guidelines prescribe the documentation and assurances
that must accompany requests for NIH funding for research using human pluripotent stem cells from human embryos or fetal tissue. The
Guidelines state specific criteria for informed consent and establish a
Human Pluripotent Stem Cell Review Group to review documentation
of compliance with the NIH Guidelines. In addition, the Guidelines delineate areas of research involving human pluripotent stem cells that
are ineligible for NIH funding.
Id.
43
Goldstein, supra note 11, at 239 (citing Juengst & Fossel, supra note 33, at
3183).
44
Id.; see also National Institutes of Health Guidelines for Research Using Human
Pluripotent Stem Cells, 65 Fed. Reg. 51976, 51979–81 (Aug. 25, 2000). Again, these
conditions, in pertinent part, rest on the distinction between cell lines derived for
research purposes and those used for research purposes.
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In August 2001, President George W. Bush announced the current federal executive policy permitting the use of federal funds
solely for research on existing stem cell lines and creating a presidential council for monitoring developments in, and establishing guide45
lines for, stem cell research. Further, President Bush promised to
veto any legislation that allows federal funding for: “(1) the derivation or use of stem cell lines derived from newly destroyed embryos;
(2) the creation of any human embryos for research purposes; or (3)
46
the cloning of human embryos for any purpose.” Therefore, the
Bush policy effectively rejects the NIH Guidelines insofar as they proscribe federal funding of stem cell research involving any stem cell
47
lines other than those already in existence. The NIH—the government’s leading organization on biomedical research—quickly followed the President’s lead:
[F]ederal funds may be awarded for research using human
embryonic stem cells if the following criteria are met: The derivation process (which begins with the destruction of the embryo)
was initiated prior to 9:00 P.M. EDT on August 9, 2001. The stem
cells must have been derived from an embryo that was created for
reproductive purposes and was no longer needed. Informed consent must have been obtained for the donation of the embryo and
48
that donation must not have involved financial inducements.

C. States’ Policy on Stem Cell Research
Notwithstanding federal restrictions on stem cell research, states
have exercised their own discretion in forming their individual poli49
cies regarding the controversial technology. State policies “range
from statutes in California, Connecticut, Illinois, Iowa, Maryland,
Massachusetts, New Jersey, and New York, which encourage embryonic stem cell research, to South Dakota’s law, which strictly forbids
50
research on embryos regardless of the source.” As indicated by New
Jersey’s and California’s policies, “some states so strongly believe in

45

Address to the Nation on Stem Cell Research from Crawford, Texas, 37 PUB.
PAPERS 32 (Aug. 13, 2001).
46
Press Release, The White House, President George W. Bush, Fact Sheet: Embryonic Stem Cell Research (Aug. 9, 2001), available at http://www.whitehouse
.gov/news/releases/2001/08/print/20010809-1.html [hereinafter Fact Sheet].
47
See id.
48
NIH’s Role in Federal Policy: Stem Cell Research, http://stemcells.nih.gov/
policy/NIHFedPolicy.asp (last visited Feb. 6, 2008) (emphasis added).
49
See Sax, supra note 19, at 21–26.
50
Nat’l Conf. of State Legislatures, Stem Cell Research, http://www.ncsl.org/
programs/health/Genetics/embfet.htm (last visited Feb. 6, 2008).
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stem cell research, either for medical, political, or economic reasons,
that they are willing to support research that the federal government
51
is not willing to presently fund.” The most recent development in
this nationwide debate was Missouri voters’ ratification of the Missouri Stem Cell Research and Cures Initiative, essentially authorizing
52
any stem cell research programs that meet the federal guidelines.
While some states are still unwilling to authorize stem cell re53
search, California and New Jersey have taken the lead in legislatively
54
permitting and declaring the benefits of stem cell research. Specifically, in becoming the first state to authorize stem cell research within
its borders, California declared in 2002 “that research involving the
derivation and use of human embryonic stem cells, human embryonic germ cells, and human adult stem cells, including somatic cell
nuclear transplantation, shall be reviewed by a stem cell research
55
oversight committee.”
California’s policy determination is based on a number of findings, such as the legislature’s conviction that “[s]tem cell research offers immense promise for developing new medical therapies for these
debilitating diseases and a critical means to explore fundamental
questions of biology. Stem cell research could lead to unprecedented
treatments and potential cures for diabetes, Alzheimer’s disease, can56
cer, and other diseases.” Furthermore, scientific advancement and
medical breakthroughs were not the only sparks for this revolutionary
policy:

51

Sax, supra note 19, at 20.
MO. CONST. art. III, § 38(d)(1)–(2).
To ensure that Missouri patients have access to stem cell therapies and
cures, that Missouri researchers can conduct stem cell research in the
state, and that all such research is conducted safely and ethically, any
stem cell research permitted under federal law may be conducted in
Missouri, and any stem cell therapies and cures permitted under
federal law may be provided to patients in Missouri, subject to the
requirements of federal law and [certain named limitations and
requirements].
Id. § 38(d)(2).
53
See, e.g., Paul Smaglik, Stem-Cell State Lines, 429 NATURE 905, 905 (2004) (discussing Missouri’s (currently outdated) and Kansas’s specific bans on stem cell research).
54
CAL. CONST., art. XXXV, amended by Proposition 71 (2004) (funding stem cell
research); CAL. HEALTH & SAFETY CODE § 125290.10 (West 2004); CAL. HEALTH &
SAFETY CODE § 125300 (West 2006) (authorizing stem cell research); N.J. STAT. ANN.
§§ 26:2Z-1, -2 (West 2004); see also infra Part II.D.
55
CAL. HEALTH & SAFETY CODE § 125300.
56
Id. § 125300(d).
52
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California’s biomedical industry is a critical component of the
state’s economy that provides employment in over 2,500 companies to over 225,000 Californians, pays $12.8 billion in wages and
salaries, invests more than $2.1 billion in research, and reports
nearly $7.8 billion in worldwide revenue, and would be signifi57
cantly diminished by limitations imposed on stem cell research.
58

Following New Jersey’s commitment to fund the technology,
the voters of California passed Proposition 71, which created the Cali59
fornia Institute for Regenerative Medicine (CIRM) and expressly allocated “an average of $295 million per year in bonds over a 10-year
period to fund stem cell research and dedicated facilities for scientists
at California’s universities and other advanced medical research fa60
cilities throughout the state.” Proposition 71 also established the
61
Independent Citizen’s Oversight Committee (ICOC), a twenty-nine
member board comprised of experts from public and private California universities, non-profit and for-profit medical research firms, and
62
disease research advocacy groups, to govern the CIRM. Moreover,
as one of the principal authors of Proposition 71 argued, the high
costs of funding stem cell research will be offset by the gains enjoyed
by California due to the economic growth expected from the promise
63
of the technology.
As it stands, despite the fervor with which Proposition 71 was enacted and promoted, the awarding of research grants has been tempered by litigation brought by challengers of the decision to fund the
64
grants through general obligation bonds. Consequently, in an ef57
58

Id. § 125300(f).
N.J. STAT. ANN. § 26:2Z-1(f).
Open scientific inquiry and publicly funded research will be essential
to realizing the promise of stem cell research and maintaining this
State’s leadership in biomedicine and biotechnology. Publicly funded
stem cell research . . . offers the most efficient and responsible means
of fulfilling the promise of stem cells to provide regenerative medical
therapies.

Id.
59

CAL. HEALTH & SAFETY CODE § 125290.10.
2004 Cal. Legis. Serv. Prop. 71 (West).
61
CAL. HEALTH & SAFETY CODE § 125290.15.
62
Id. § 125290.20(a).
63
Sax, supra note 19, at 23 (citing Connie Bruck, Hollywood Science, NEW YORKER,
Oct. 18, 2004, at 70 (discussing how Robert Klein, a California real estate mogul and
author of Proposition 71, proposed funding the Institute)).
64
See Press Release, California Institute for Regenerative Medicine, Appellate
Court Sets Hearing for Stem Cell Litigation (Jan. 18, 2007), available at http://www.
cirm.ca.gov/press/pdf/2007/01-18-07.pdf (explaining plaintiffs’ appeal from lower
court’s ruling that funding through general obligation bonds is constitutional and
not in violation of any statutes or government oversight duties).
60
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fort to encourage the policy despite the obstacles presented by this
litigation, Governor Schwarzenegger ordered a $150 million loan in
August 2006, largely provided by a fund comprised of money from
private philanthropists and organizations, allowing CIRM to presently
65
solicit proposals for grants.
Other states have since followed California’s and New Jersey’s
66
lead by at least authorizing, if not also funding, stem cell research.
For instance, in 2005, the Connecticut General Assembly established
its Stem Cell Research Fund which, not unlike California, consists of
“not less than ten million dollars . . . for grants-in-aid to eligible institutions for the purpose of conducting embryonic or human adult
67
68
stem cell research,” for a ten-year period that began in June 2006.
Similarly, following a 2005 executive order signed by Governor
69
Blagojevich, Illinois maintains that it “is at the forefront of stem cell
research as the first Midwest state, and only the fourth state in the nation, to commit public dollars to support this ground-breaking sci70
ence.” Upon creating the Illinois Regenerative Medicine Institute
(IRMI), Governor Blagojevich transferred ten million dollars in
71
budget funds to the program. Subsequently, the IRMI awarded its
first grants in April 2006, and the health department has appropriated five million dollars from its budget to the stem cell research
72
program for fiscal year 2007.
Taking a smaller but no less significant step, the Indiana General
Assembly authorized Indiana University to “establish an adult stem
73
cell research center.” Thus far, Indiana has allocated fifty thousand
74
dollars toward establishing the center. In 2006, the Maryland Gen65

Press Release, California Institute for Regenerative Medicine, $181 Million
Headed for Stem Cell Institute (Nov. 20, 2006), available at http://www.cirm.ca.gov/
press/pdf/2006/11-20-06.pdf; see also Governor Arnold Schwarzenegger, Discussion
of Executive Action to Strengthen Stem Cell Research (July 21, 2006), available at
http://gov.ca.gov/index.php?/speech/2538/.
66
See generally Nat’l Conf. of State Legislatures, supra note 50 (providing a concise
summary and chart of state legislation and executive orders permitting and funding
stem cell research).
67
CONN. GEN. STAT. § 19a-32e(c) (2005).
68
Id.
69
Exec. Order No. 2005-6, Executive Order Creating the Illinois Regenerative
Institute for Stem Cell Research (July 12, 2005).
70
Illinois Regenerative Medicine Institute, About IRMI, http://www.idph.state.il.
us/irmi/about.html (last visited Oct. 23, 2006).
71
Exec. Order No. 2005-6, supra note 69; see also Nat’l Conf. of State Legislatures,
supra note 50.
72
Nat’l Conf. of State Legislatures, supra note 50.
73
IND. CODE ANN. § 21-45-4-1 (West 2007).
74
Nat’l Conf. of State Legislatures, supra note 50.
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eral Assembly adopted a similar program when it established the
Maryland Stem Cell Research Fund, to distribute grants for research
75
conducted on adult and embryonic stem cells. Maryland has allocated fifteen million dollars for the Stem Cell Research Fund for fis76
cal year 2007.
Seeking a more developed and expansive policy, the Massachusetts legislature enacted two statutory provisions demonstrating the
77
state’s interest in fostering stem cell research. The first establishes a
78
“biomedical research advisory council” that combines the efforts
and experiences of several officials from the state’s department of
79
The
health and the University of Massachusetts Medical School.
second provision announces that:
[T]he purpose of this chapter is to establish a life sciences center
. . . intended to: (i) promote the best available research in life sciences disciplines through diverse institutions and to build upon
existing strengths in the area of biosciences in order to spread the
economic benefits across the commonwealth; and, (ii) foster improved health care outcomes in the commonwealth and the
80
world.

The latter provision also provides funding for the program with the
81
Life Sciences Investment Fund. It is important to note, however,
that the general court enacted these provisions after overriding Governor Romney’s veto of the proposed pro-stem cell research legisla82
tion.
Hesitant states (yet willing nonetheless) continue to contemplate
stem cell research, enacting limited legislation that gradually demon-

75
76
77
78
79
80
81

MD. ANN. CODE art. 83A, § 5-2B-03 (2006).
Id.; see also Nat’l Conf. of State Legislatures, supra note 50.
MASS. ANN. LAWS ch. 111L, § 9 (LexisNexis 2006); id. ch. 23I, § 1(8)–(9).
Id. ch. 111L, § 9(a).
Id.
Id. ch. 23I, § 1(8)–(9).
Nat’l Conf. of State Legislatures, supra note 50.
The second establishes a life sciences center to promote life sciences
research in advanced and applied sciences, including but not limited to
stem cell research, regenerative medicine, biotechnology, and
nanotechnology and creates the Life Sciences Investment Fund to
make appropriations, allocations, grants or loans to leverage development and investments in stem cell research and other areas.
$10,000,000 was appropriated to the fund.

Id.
82

Id.
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strates such states’ readiness to permit the controversial experimenta83
tion. In sum:
Even though the federal government is not funding laboratories that want to establish new stem cell lines, public money is still
being used to promote this research at the state level. Researchers wishing to engage in frontier science have limited choices.
They can either attempt to solicit private funding at the institute
where they currently research or move to a state with a commit84
ment to funding the research.

D. New Jersey’s Stem Cell Research Policy
New Jersey passed legislation in January 2004 authorizing and
85
encouraging stem cell research. “The New Jersey bill allows all types
of stem cell research[,] . . . sets up an institutional review board to review stem cell research, and states that information will be presented
to infertility patients about their options to donate unused embryos
86
to research.”
87
A major catalyst for New Jersey’s “proclamation” was the state’s
recognition that “[t]he biomedical industry is a critical and growing
component of New Jersey’s economy, and would be significantly di88
minished by limitations imposed on stem cell research.” In view of
that, in May 2004, New Jersey became the first state to publicly fund
stem cell research when Governor James McGreevey signed legislation that established “the nation’s first state-supported stem cell re89
search facility.” In addition, during his term as Acting Governor of
New Jersey, Richard Codey issued an executive order “solidifying New
Jersey’s position as a scientific leader through the creation of a public
umbilical cord and placental blood bank for use in stem cell re83

See, e.g., WASH. REV. CODE § 43.350.005 (2006) (setting up a rather open ended
scheme by which the Washington State Legislature discusses the benefits of stem cell
research and authorizes a life sciences discovery fund that may result in future grants
for stem cell research); see also The Christopher Reeve Stem Cell Research Fund, VA.
CODE ANN. § 23-286.1 (2006) (authorizing a fund consisting of money to “be used
solely to support medical and biomedical stem cell research conducted in Virginia
institutions of higher education that relates to the causes and cures of disease,” but
not specifically providing any money for the fund).
84
Sax, supra note 19, at 25–26.
85
N.J. STAT. ANN. §§ 26:2Z-1, -2 (West 2006); see also Detrizio & Brennan, supra
note 6.
86
Sax, supra note 19, at 21; see generally N.J. STAT. ANN. §§ 26:2Z-1, -2.
87
Jeremy Pearce, Entering a Brave New World, Warily, N.Y. TIMES, Jan. 18, 2004, at
14NJ1.
88
N.J. STAT. ANN. § 26:2Z-1(e).
89
David Kocieniewski, McGreevey Signs Bill Creating Stem Cell Research Center, N.Y.
TIMES, May 14, 2004, at B5.
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90

search.” This measure entrusts all the research and financing to the
Stem Cell Institute, instead of spreading the funds throughout the
91
state like California’s Proposition 71; it also encourages New Jersey
92
scientists to collaborate with researchers from around the world.
New Jersey took another step as a pioneer in funding stem cell
research in December 2005 when its Commission on Science and
Technology granted five million dollars to seventeen New Jersey educational, nonprofit, and corporate research teams for cutting-edge
exploration of potential cures and treatments for devastating and de93
bilitating conditions.
Governor Jon Corzine approved legislation
that allocates $270 million to construct and equip several stem cell
94
research laboratories throughout the state. However, New Jersey’s
efforts to fund the cutting edge research suffered an unexpected setback in November 2007, when voters rejected a measure that would
have allowed the state to borrow up to $450 billion over the next ten
95
years to fund stem cell research. Notwithstanding this interruption
to New Jersey’s momentum, the remainder of this Comment focuses
on the intellectual property implications that are likely to arise as
New Jersey continues to remain at the forefront of stem cell research.

90

Press Release, New Jersey Office of the Governor, Codey Announces Pioneering Stem Cell Research Initiative (Oct. 18, 2005), available at http://www.nj.gov
/cgi-bin/governor/njnewsline/view_article.pl?id=2780.
91
See CAL. CONST. art. XXXV, amended by Proposition 71 (2004); CAL. HEALTH &
SAFETY CODE § 125290.10 (West 2006); see also supra notes 60–65.
92
State of New Jersey Commission on Science & Technology, The Stem Cell Institute of New Jersey, http://www.state.nj.us/scitech/stemcell/institute (last visited
Feb. 21, 2008) [hereinafter N.J. Stem Cell Inst.]; see also CAL. CONST. art. XXXV,
amended by Proposition 71 (2004); CAL. HEALTH & SAFETY CODE § 125290.10; see also
supra notes 60–65.
93
N.J. Sci. & Tech., supra note 7 (“In December 2005 the Commission awarded
the Ellie Katz Umbilical Cord Blood Program and the Coriell Institute for Medical
Research $350,000 each to create the nation’s first public cord and placental blood
bank for stem cell research.”).
94
N.J. Stem Cell Inst., supra note 92.
95
Terrence Dopp, New Jersey Rejects Stem-Cell Bonds in “Big Defeat,”
BLOOMBERG.COM, Nov. 7, 2007, http://www.bloomberg.com/apps/news?pid=206010
87&sid=azGJAFWSMcjs&refer=home.
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III. SIDE EFFECTS OF PUBLICLY
FUNDED STEM CELL RESEARCH PROGRAMS AND THEIR
LIKELY MANIFESTATION IN NEW JERSEY
A. Intellectual Property Implications Encountered Under Other Publicly
Funded Stem Cell Research Programs
“[B]ecause [stem cell] research will most likely proceed under
some combination of federal, state, local, non-profit and private forprofit funding sources, the ownership rights will be anything but
96
That is, unlike the simplest scenario, in which a private
clear.”
company is the sole source of funding for its own research, and contractual provisions govern most potential intellectual property disputes with employed scientists, problems may, and often do, arise in
97
the context of state entities funding scientific research.
Generally, the addition of any source of funding—whether state,
corporate, or private grant, for example—only further complicates
98
the already hazy question of intellectual property ownership. Yet,
unfortunately, it is unlikely that the confusion surrounding intellectual property rights in the arena of stem cell research will lead to
strictly private funding, as the requisite amount of funding will hardly
99
be procurable from one source.
The official scholarly rebuttals to California’s Proposition 71, released in the election materials shortly before the state-wide vote on
the measure, best crystallize the murky intellectual property implica100
tions arising under state-funded stem cell research programs. “The
Argument Against Proposition 71 . . . focused largely on the ‘boondoggle’ aspects of the measure, including a lack of accountability, closeddoor meetings, and the funneling of a staggering amount of money

96

Sean M. O’Connor, Intellectual Property Rights and Stem Cell Research: Who Owns
the Medical Breakthroughs?, 39 NEW ENG. L. REV. 665, 666 (2005).
97
Id. at 667–68 (explaining that private companies employing innovative workforces attempt to avoid such problems with explicit contractual provisions; however,
in a situation where a state-funded university uses those funds to finance a researcher
and his lab, “any patentable inventions that the researcher invents in the course and
scope of his employment with the university must be assigned to the university”).
98
E.g., 17 U.S.C. § 201(b) (2000) (demonstrating copyright issues arising in
work-for-hire contexts); see O’Connor, supra note 96, at 668–69; see also DONALD S.
CHISUM ET AL., PRINCIPLES OF PATENT LAW: CASES AND MATERIALS 72 n.3 (3d ed. 2004)
(explaining similar concerns germane to patent law).
99
See O’Connor, supra note 96, at 670.
100
See ATT’Y. GEN., PROPOSITION 71: OFFICIAL TITLE AND SUMMARY, at 72–73, available at http://www.ss.ca.gov/elections/bp_nov04/prop_71_entire.pdf; see also
O’Connor, supra note 96, at 676–79.
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to ‘corporate research’ that would ultimately result in windfall profits
101
to private corporations.”
102
For example, Mitch Kapor, a renowned software developer
who serves as President and Chair of the Open Source Applications
103
Foundation, applied the aforementioned critiques to the intellectual property context of Proposition 71 in a letter that was widely dis104
105
seminated days before the vote. Of Kapor’s myriad concerns, the
most germane to this Comment asserts that Proposition 71 will give
rise to ownership disputes between the private venture capitalists who
106
Ironiwill fund the research and the scientists who will conduct it.
cally, Proposition 71 evinces this distressing ambiguity in its own provision addressing the intellectual property issues:
[A]ll grants and loan awards [are] subject to intellectual property
agreements that balance the opportunity of the State of California
to benefit from the patents, royalties, and licenses that result from
basic research, therapy development, and clinical trials with the
need to assure that essential medical research is not unreasonably
107
hindered by the intellectual property agreements.

At least one commentator has argued that such language leaves
108
the intellectual property issues entirely too unresolved.
“In the abstract this [statutory provision] sounds reasonable and desirable
enough. But, the devil is in the details: Proposition 71 essentially
hands off determination of the correct balance and the means to effectively achieve that balance to the brand new and untested
101

O’Connor, supra note 96, at 676–77 (citing ATT’Y. GEN., supra note 100, at 73).
Mitchell Kapor, Biography, http://www.kapor.com/bio/index.html (last visited Feb. 6, 2008).
He is widely known as founder of Lotus Development Corporation
and the designer of Lotus 1-2-3, the “killer application” which made the
personal computer ubiquitous in the business world in the 1980’s. He
has been at the forefront of the information technology revolution for
a generation as an entrepreneur, investor, social activist, and philanthropist.
Id.
103
Open Source Applications Foundation, http://www.osafoundation.org/ (last
visited Feb. 6, 2008) (“OSAF is a non-profit organization working on Chandler Project, a personal information manager designed for small group collaboration.”).
104
Posting of Chris Nolan, Just Say “No” Says Mitch, POLITICS FROM LEFT TO RIGHT,
http://www.chrisnolan.com/archives/000577.html#more (OCT. 26, 2004, 10:00
PST).
105
See id. Kapor’s concerns regarding Proposition 71 range from the potential for
conflicts of interest, to insufficient accountability provisions, to the familiar ethical
considerations routinely debated nationwide. Id.
106
Id.
107
CAL. HEALTH & SAFETY CODE § 125290.30(h) (West 2004).
108
O’Connor, supra note 96, at 678–79.
102
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109

ICOC.”
The crux of this concern is that “Californians were asked
to vote blindly for a $3 billion investment gambit whose IP rights and
return on investment rules and procedures have yet to be established
110
in any effective or binding manner.”
Comparing the unease created by Proposition 71 and the ICOC
to the context of such blind-faith investing of taxpayers’ dollars in
cutting-edge research, one reporter hypothesized:
Imagine that a partnership of scientists and Hollywood moguls
urged you to invest in a promising but controversial field of medical research.
The partnership would control how your money is spent, based
on recommendations from appointed “working groups” whose
meetings would be kept secret from you.
111
Would you accept such a deal? Probably not.

Thus, without an effective intellectual property structure in
place clearly allocating intellectual property rights before the promise of stem cell research is realized, “the nightmare tussles over ownership and control will begin . . . [and] [t]his clamor will increase
112
That is, “stem cell
proportionally to the success of the therapies.”
113
research will be a victim of its own success” when public access is
obstructed by either a chilled incentive for researchers because of an
unfair share in ownership, or exorbitant prices for the therapies that
114
arise from the work of innovators with too much private control.
B. Manifestation of Intellectual Property Implications Likely to Arise
Under New Jersey’s Stem Cell Research Policies
New Jersey’s stem cell research policy, although motivated by the
desire to spark innovation and maintain the state’s status as a bio115
medical leader, is ominously quiet regarding allocation of intellec116
While New Jersey expressly recognizes importual property rights.
tant governing principles of its stem cell research policy including
“standards of open scientific exchange, peer review[,] and public

109

Id. at 678.
Id.
111
Stuart Leavenworth, The Opaque Petri Dish, SACRAMENTO BEE, Jan. 9, 2005, at E1.
112
O’Connor, supra note 96, at 689.
113
Id. at 687.
114
Id. at 687–89.
115
N.J. STAT. ANN. § 26:2Z-1(f) (West 2006) (“Open scientific inquiry and publicly
funded research will be essential to realizing the promise of stem cell research and
maintaining this State’s leadership in biomedicine and biotechnology.”).
116
See id.; see also N.J. Sci. & Tech., supra note 7.
110
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117

oversight,” the state’s purported aspirations such as “develop[ing]
innovative treatments for patients and generat[ing] economic oppor118
tunity and job growth in New Jersey” fail to provide any assurances
119
to the innovators that they will receive adequate ownership rights.
As such, despite these good intentions, New Jersey’s stem cell research policy may regrettably suffer the consequences that the
120
aforementioned critics of California’s Proposition 71 predicted.
Such infirmities are present throughout New Jersey’s statutes, as
well as in other substantive policy statements, evidencing the poten121
tial for intellectual property murkiness.
Primarily, in its apparent
mission statement, New Jersey declares its stem cell initiative’s commitment to “advance New Jersey’s position as a leader in scientific research . . . encourage . . . innovative treatments . . . support groundbreaking research . . . [and] generate economic opportunity and job
122
growth.”
Of course, in the United States, such goals are best
achieved “by securing for limited Times to . . . Inventors the exclusive
123
Right to their respective . . . Discoveries.”
Despite this vagueness, New Jersey has at its disposal two measures that at least provide a foundation upon which to build an ade124
quate intellectual property scheme. First, unlike the relative silence
125
throughout the statutes authorizing stem cell research, the Stem
Cell Research Grant Program expressly provides that “[r]ecipient organizations will be required to share with the State of New Jersey a
percentage of any income received from the intellectual property
126
that might be developed with the State’s grant support.” While this
“guarantees that the state will receive a direct financial benefit from
127
any commercial licensing,” it does little to clarify the quantity of
that benefit, or what portion of the commercial benefits the grantee
117

N.J. STAT. ANN. § 26:2Z-1(f).
N.J. Sci. & Tech., supra note 7.
119
See id.; see also N.J. STAT. ANN. §§ 26:2Z-1, -2 (West 2006).
120
See supra Part III.A.
121
See N.J. STAT. ANN. §§ 26:2Z-1, -2; N.J. Sci. & Tech., supra note 7.
122
N.J. Sci. & Tech., supra note 7 (emphasis added).
123
U.S. CONST. art. I, § 8, cl. 8.
124
See State of New Jersey Commission on Science & Technology, Stem Cell Research Grant Program, http://www.state.nj.us/scitech/stemcell/grants/faqs.html
(last visited Feb. 6, 2008) [hereinafter Stem Cell Research Grant Program]; State of
New Jersey Commission on Science & Technology, Entrepreneur Assistance,
http://www.state.nj.us/scitech/entassist/ (last visited Feb. 6, 2008) [hereinafter Entrepreneur Assistance].
125
N.J. STAT. ANN. §§ 26:2Z-1, -2.
126
Stem Cell Research Grant Program, supra note 124.
127
Id.
118
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can expect; yet it at least provides a starting point within the statutory
framework.
Within New Jersey’s intellectual property toolbox is its Edison
128
Innovation R&D Fund (“Edison Fund”).
The Edison Fund was designed to fund companies involved in early, high-risk stages of scien129
tific and technological research and development. Pertinent to this
Comment, a main goal of the Edison Fund is to “increase[] the
130
amount and value of intellectual property” created by such companies. Underlying the Edison Fund are the familiar goals to “promote[] collaboration between universities and companies . . . and
131
grow[] technology businesses in New Jersey” —further evidence of
New Jersey’s commitment to remain a leader in biotechnology.
Unlike the concerns presented by the aforementioned poli132
cies, the Edison Fund materials provide some quantitative guidance
as to royalty distribution using language similar to that of the Stem
Cell Research Grant Program, but taking it one step further:
The Commission shall receive a percentage of royalty payments
from any intangible property awarded to the grantee awarded assistance from the Commission and which assistance led to the
awarding of the intangible property pursuant to New Jersey Statutes, P.L. 2005, c.272 as follows:
• 1% of net sales resulting from IP developed under the
grant—up to the original amount of the grant.
• 1% of royalty payments received by the company for licensing IP developed under the grant—up to 10 times
the original amount of the grant[.] 133

Under this administrative scheme, the Edison Fund caps the maximum amount of royalties payable to the State by the innovator at ten
times the amount of the original grant, thereby providing clear
134
guidelines for allocation of royalties to all interested parties.
Nevertheless, all regulation of stem cell research in New Jersey
falls under the rubrics of the Stem Cell Institute of New Jersey and
the Stem Cell Research Grant Program because the Edison Fund is
primarily a competition-encouraging mechanism designed to foster
128

Entrepreneur Assistance, supra note 124.
Id.
130
Id.
131
Id.
132
See supra Part III.A.
133
STATE OF N.J. COMM’N ON SCI. & TECH., EDISON INNOVATION R&D FUND
APPLICATION GUIDELINES 5 (2007), available at http://www.state.nj.us/scitech/pdf/
entassist/edisonrdguidelines07.pdf.
134
Id.
129
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technological innovation by private companies that may or may not
135
collaborate with a state research institution. Consequently, the Edison Fund’s unique clarity regarding intellectual property rights and
royalty allocation can presently serve in no more than an advisory capacity.
In attempting to discern their intellectual property rights when
funded by these programs, researchers must look to existing New Jersey intellectual property law applicable to work funded by the state’s
136
science and technology grant program. Not surprisingly, this provision offers a quantitatively nebulous explanation of allocation of intellectual property rights to royalties:
[The New Jersey Commission on Science and Technology] shall
have authority to receive a percentage of royalty payments from
any intangible property . . . awarded to any science and technology company that received assistance from the commission and
which assistance led to the awarding of the intangible property
137
[in exchange for certain financial and other obligations.]

Thus, while New Jersey’s intentions, coupled with foundational
intellectual property plans, provide a benevolent and fertile environment in which to develop the state’s budding stem cell research
frontier, the state needs specific and clear provisions addressing these
issues. “This crisis, and its concomitant challenge to the social order
and existing IP ownership structure, must be averted by taking proactive measures now. In fact, some sorting and planning of ownership claims that correspond to funding sources can be effected today
138
for new stem cell research initiatives.”

135

Entrepreneur Assistance, supra note 124. “The Edison Innovation R&D Fund
will provide grants on a competitive basis.” Id. “Companies are encouraged to partner with any New Jersey PhD granting universities or with any company or institution
with primary business location in New Jersey.” Id. Moreover, to be eligible, companies must be “[o]rganized as a C Corp or an LLC.” Id.; see also supra Part II.D.
136
See N.J. STAT. ANN. § 52:9X-9 (West 2006). Thus, in crafting a regulatory
scheme for state-funded stem cell research, New Jersey lawmakers cannot simply rely
on the Edison Fund to govern these concerns since it only affects state institutions if
they are partnered with an eligible “lead company.” See supra note 135 and accompanying text.
137
Id. § 52:9X-9(u). That is, the Commission does little to provide notice to potential innovators regarding the actual amount of royalties they should expect to
share with the state. See Stem Cell Research Grant Program, supra note 124. While
this seems to leave open only the question of the amount of royalties, other, more
comprehensive, policy regimes demonstrate that there are a number of other concerns—including surrendering, relaxing, and guaranteeing certain rights—that must
be addressed by a successful policy. See infra Part IV.
138
O’Connor, supra note 96, at 666.
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IV. APPLICATION OF OTHER LEGISLATIVE AND REGULATORY SCHEMES:
TOWARD A PROPOSAL TO AVOID CONFLICT IN NEW JERSEY
As suggested above, New Jersey must delineate clearer guidelines
regarding intellectual property rights as the state begins to realize the
burgeoning potential of stem cell research. New Jersey’s policies regarding budding technologies such as stem cell research—with all the
benefits that it promises—should provide more clarity rather than
simply acknowledging that the state will receive some indefinite percentage of the income generated through intellectual property royalties. This clarity should come in the form of not only a precise royalty
distribution framework, but also a satisfactory balance of rights and
compromises between innovators and the state in exchange for both
parties’ surrendering of certain exclusivities.
Accordingly, while these measures are a significant starting
139
point, this Comment advocates that learning from other legislative
and policy schemes will provide valuable assistance in addressing this
problem. These schemes are California’s Intellectual Property Policy
140
for Non-Profit Organizations, the National Science Foundation’s
141
142
(NSF) grant policy governed by the Bayh-Dole Act, and the Fed143
eral Orphan Drug Act.
A. CIRM’s Intellectual Property Policy for Non-Profit Organizations
As New Jersey’s chief fellow pioneer on the frontier of stem cell
research, CIRM functions as the west coast equivalent to the Stem
Cell Institute of New Jersey. As such, California’s policy addressing
these issues is of particular significance. In pertinent part, CIRM’s
144
policy declares its “core principles” to be: “1. Ownership; 2. Broad
Sharing; 3. Research Exemption; 4. Licensing; [and] 5. March-in
145
rights.”
139

See supra Part II.B.
CAL. INST. FOR REGENERATIVE MED., INTELLECTUAL PROPERTY POLICY FOR NONPROFIT ORGANIZATIONS (2006), http://www.cirm.ca.gov/policies/pdf/ippnpo.pdf.
CIRM is also developing a separate policy applicable to for-profit organizations. Id.
See also supra Part III.A.
141
Policies and Procedures for Inventions and Patents Resulting from Grants, Cooperative Agreements, and Contracts, 45 C.F.R. § 650 (1982); see also NAT’L SCI.
FOUND., GRANT POLICY MANUAL 95–102 (2005), http://www.nsf.gov/pubs/manuals/
gpm05_131/gpm05_131.pdf; infra Part III.B.
142
Bayh-Dole Act, Pub. L. No. 96-517, 94 Stat. 3015 (1980) (codified as amended
at 35 U.S.C. §§ 200–210 (2000)); see also infra Part IV.B.
143
Orphan Drug Act, 21 U.S.C. §§ 360aa–ee (2000) (originally enacted as Pub. L.
No. 97-414, 96 Stat. 2049 (1983)).
144
CAL. INST. FOR REGENERATIVE MED., supra note 140, at 22.
145
Id. at 22–23.
140
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These provisions allow all grantees of CIRM funds to own the intellectual property arising from the Institute’s financing, while encouraging a liberal sharing policy throughout the scientific and edu146
cational communities.
Although the owner-inventors will maintain
ownership of all intellectual property, certain patented inventions will
147
Such
remain freely available to California research institutions.
grantees of CIRM funds “are expected to negotiate non-exclusive licensing agreements where possible . . . to encourage the successful
commercial development of the invention into products and services
148
that can benefit the public.” In an effort to balance the ownership
interests of the inventors with CIRM’s public welfare interests, the
policy provides a march-in rights provision, which grants CIRM the
ability to practically apply a patented invention when the inventor
149
demonstrates underutilization of licensing amounting to waste.
Thus, as a state with a comparable policy and attitude concerning stem cell research, New Jersey would be well-served to implement
a similar intellectual property policy. The California policy “is intended to meet the dual goals of academic openness and the need to
bring scientific advances to the public via commercialization” while
also “facilitate[ing] the commercialization of CIRM-funded discover150
ies without impeding the progress of stem cell research.”
This intellectual-property-geared language seems strikingly consistent with
New Jersey’s goals for its stem cell research program:
New Jersey’s stem cell research initiative is committed [t]o advanc[ing] New Jersey’s position as a leader in scientific research
and bring[ing] the benefits of stem cell research to New Jersey
residents[; t]o encourage[ing] and enable[ing] the state’s renowned research and life sciences communities to develop quality, innovative treatments for patients[; t]o support[ing] groundbreaking research that contributes to the understanding of stem
cells and their potential and the translation of such research to
patient treatment[; and t]o generat[ing] economic opportunity
and job growth in New Jersey by accelerating commercialization
146

Id. at 22.
Id.
148
Id. at 23.
149
Id. at 23, 37–38.
Prior to exercising march-in rights, CIRM must determine that such action is necessary because of the failure of the grantee organization or
its licensees to take effective steps to achieve practical application of
the inventions in a particular field of use, to satisfy health or safety
needs, or to meet requirements for public use.
Id. at 37.
150
CAL. INST. FOR REGENERATIVE MED., supra note 140, at 4–5.
147
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of new therapies and new technologies related to stem cell re151
search.

Thus, as the Stem Cell Institute of New Jersey formulates its intellectual property policy, it should consider what CIRM, its copioneer in the arena of stem cell research, has adopted in California.
Such a clear description of ownership rights, coupled with even
clearer royalty allocation language as that found in New Jersey’s Edi152
son Fund, demonstrates an ideal foundation on which to build a
suitable intellectual property framework.
B. The NSF Grant Policy and the Bayh-Dole Act
As the main governmental agency charged with funding scien153
tific innovation with federal money, the NSF is an ideal reference
point from which New Jersey can model its intellectual property policies regarding stem cell research. In 1982, the NSF updated its regulations governing inventions and patents borne from NSF-granted
154
The impetus for this policy revision was the NSF’s
federal funds.
objective to align its treatment of such intellectual property with the
155
governmental interests set forth in the Federal Bayh-Dole Act.
With the passage of Bayh-Dole, Congress sought to strike a balance—similar to that envisioned by this Comment—by altering the
federal patent policy in order to reconcile the government’s ownership interest with that of fostering modern technological innova-

151

N.J. Sci. & Tech., supra note 7.
Supra note 133 and accompanying text.
153
National Science Foundation, http://nsf.gov/about/ (last visited Mar. 17,
2008).
The National Science Foundation . . . is an independent federal agency
created by Congress in 1950 “to promote the progress of science; to advance the national health, prosperity, and welfare; [and] to secure the
national defense . . . .” With an annual budget of about $6.06 billion,
[the NSF is] the funding source for approximately 20 percent of all
federally supported basic research conducted by America's colleges and
universities.
Id.
154
National Science Foundation Patent Policy, 45 C.F.R. § 650.2 (2000).
155
Id. “The regulation replaces all current NSF patent regulations and brings
NSF patent policies and procedures into compliance with the Bayh-Dole Act. The
policies and procedures set forth apply to all grants and cooperative agreements
awarded by the Foundation since July 1, 1981 . . . .” Id.; see also NAT’L SCI. FOUND.,
supra note 141, at 95. “The disposition of rights to inventions made by small business
firms and non-profit organizations, including universities and other institutions of
higher education, during NSF-assisted research is governed by . . . the Bayh-Dole
Act.” Id.
152
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156

tion.
As a practical matter, the Bayh-Dole Act served to grant “universities and small businesses the right to own their inventions made
157
The provisions set forth by Bayh-Dole provide
with federal funds.”
valuable insight to New Jersey as such a regulatory scheme seems to
be a healthy approach to realizing governmental aspirations while
158
balancing the interests of award grantees.
More specifically, Congress struck this balance by granting certain minimum rights to the government while simultaneously imposing certain requirements on grantees, namely businesses and univer159
For instance, regarding governmental rights, Bayh-Dole
sities.
requires that all such funding contracts include a clause granting the
160
government a paid-up license to use the patented invention.
Under this provision, neither the government nor any of its contractors
could be held liable for patent infringement for the use of an inven161
Another notable benefit afforded the government
tion it funded.
under Bayh-Dole is Congress’s grant of march-in rights, whereby the
government—as a matter of right—may require the grantee to li-

156

See Bayh-Dole Act, 35 U.S.C. § 200 (2000). Congress used language that echoes
New Jersey’s goals for its stem cell policy, as well as the goals contemplated in this
Comment.
It is the policy and objective of the Congress to use the patent system to
promote the utilization of inventions arising from federally supported research or
development; . . . to ensure that inventions made by nonprofit organizations and small business firms are used in a manner to promote free competition and enterprise without unduly encumbering future research and discovery;
. . . to ensure that the Government obtains sufficient rights in federally supported
inventions to meet the needs of the Government and protect the public
against nonuse or unreasonable use of inventions . . . .
Id. (emphasis added).
157
John H. Raubitschek, Responsibilities Under the Bayh-Dole Act, 87 J. PAT. &
TRADEMARK OFF. SOC’Y 311, 311 (2005). Large business became subject to certain
provisions of the Bayh-Dole Act when Congress amended the act in 1984. See BayhDole Act, 35 U.S.C. § 210 (2000).
158
See, e.g., Raubitscheck, supra note 157, at 311. “Under the Bayh-Dole Act, universities have been very successful in commercializing their inventions. According to
surveys by the Association of University Technology Managers . . . , universities
earned over $1 billion in royalties annually from FY 2000[–2003].” Id.
159
See generally 35 U.S.C. §§ 200–210; see also Raubitschek, supra note 157, at
311–18.
160
35 U.S.C. § 202(c)(4).
161
Raubitschek, supra note 157, at 312. Further, “[t]he Government’s rights may
be expanded to cover other governments as are necessary to meet obligations under
any treaty, international agreement or memorandum of understanding.” Id. (citing
§ 202(c)(4) of the Bayh-Dole Act).
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cense a patent when the grantee has not sufficiently commercialized
162
the invention or when the grantee’s conduct amounts to waste.
On the other side of the balance, a major result of Bayh-Dole
was the granting of absolute ownership of, and other rights regard163
ing, their federally funded inventions to grantees.
President
Reagan’s Memorandum on Government Patent Policy of 1983, an
early example of these benefits, made clear the need for “waiving
some of the Government’s rights and the contractor’s obligations
under [Bayh-Dole] to obtain a uniquely or highly-qualified contrac164
tor.”
Similarly, Bayh-Dole was sure to alleviate any concern that the
government’s enumerated rights would apply even if only a minimal
amount of government funds were used in conceiving the inven165
tion.
That is, in order for the government to exercise its rights,
“the funds must have been used in either the conception or first ac166
While superficially Bayh-Dole seems to
tual reduction of practice.”
grant more rights to the government, there are relatively minimal assurances that government funds will not be abused, as they are generally subject to the plenary interest of the Act—granting ownership
to and fostering innovation within the scientific community.
To that end, the NSF revamped its own intellectual property policy in order to “better serve the purposes of [Bayh-Dole] or the inter167
ests of the United States and the general public.” At the very minimum—in situations where the grantee has elected not to retain title
168
in his NSF-funded invention —“[t]he grantee will retain a nonexclusive royalty-free license throughout the world in each subject invention to which the Government obtains title, except if the grantee
fails to disclose the subject invention within [the time specified by the

162

35 U.S.C. § 203. While the necessity to exercise march-in rights has proved to
be rare, see Raubitschek, supra note 157, at 312–13 (referencing, e.g., Johns Hopkins
Univ. v. CellPro, Inc., 152 F.3d 1342 (Fed. Cir. 1998)), it nevertheless provides the
government with peace of mind when issuing the grant, while simultaneously presenting a significant incentive for the grantee to make the most of his federal funding and resulting innovation.
163
Raubitschek, supra note 157, at 311.
164
Memorandum on Government Patent Policy, 1983 PUB. PAPERS 248, 252 (Feb.
18, 1983). This particular grant of flexibility was arguably weakened by the 1984
amendment to the Act, which subjected the rights of large businesses to the government’s license and march-in rights. See Raubitschek, supra note 157, at 311.
165
See Raubitschek, supra note 157, at 313.
166
Id.
167
National Science Foundation Patent Policy, 45 C.F.R. § 650.2(a) (2006).
168
Id. § 650.4(e)(1).
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169

NSF policy].”
Similarly, “[i]f an awardee elects not to retain rights
to an invention, the Foundation will allow the inventor to retain the
principal patent rights unless the awardee . . . shows that it would be
170
Thus, unlike New Jersey’s existing stem
harmed by that action.”
cell research policy, the NSF policy first sets forth a minimum level of
171
protection for all NSF-funded innovators.
Further, the NSF’s adaptation of Bayh-Dole to its patent policy
provides guidance regarding greater grantee rights, which could
prove to be a useful starting point for New Jersey when crafting a
clearer intellectual property policy:
The grantee may retain the entire right, title, and interest
throughout the world to each subject invention subject to the
provisions of this Patents Rights clause and [Bayh-Dole]. With respect to any subject invention in which the grantee retains title,
the Federal Government shall have a nonexclusive, nontransferable, irrevocable, paid-up license to practice or have practiced for
or on behalf of the United States the subject invention through172
out the world.
173

174

Although this provision and the remainder of the NSF policy
do not offer any specific royalty allocation guidelines, the NSF’s policy, coupled with appropriate language such as that of New Jersey’s
175
Edison Fund, would serve as a constructive aid to New Jersey policymakers as they develop a clear intellectual property policy for statefunded stem cell research.
C. The Orphan Drug Act
A third regulatory scheme—and more of an example of what
happens when proper incentives are not in place than a substantive
policy template—that New Jersey should consider in forming its intellectual property policy for its stem cell initiative is the Orphan Drug
Act, a federal law enacted over twenty years ago in order to remedy
private industry’s failure (due to an insufficient market) to produce
176
drugs for rare diseases (“orphan drugs”).
Congress enacted the
Orphan Drug Act in 1983 because pharmaceutical companies could

169
170
171
172
173
174
175
176

Id.
Id. § 650.2(c).
See supra Part III.B.
45 C.F.R. § 650.4(b).
See id.
See generally id. § 650.
See supra notes 128–34 and accompanying text.
Orphan Drug Act, 21 U.S.C. §§ 360aa–ee (2000).
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not afford to develop drugs for rare diseases due to the inherently
177
small market for such drugs. Through this Act, Congress hoped to
create financial incentives to ensure that pharmaceutical companies
would develop treatments for these diseases to which such little atten178
tion had been paid in the past.
To that end, the Orphan Drug Act sets forth several incentives
for innovators who invent cures for rare diseases. These incentives
are largely financial in nature and include exclusive licensing, tax
credits, federal funding for clinical trials and research, and other
179
grants for developers of orphan drugs.
The significance of an incentive program like the Orphan Drug
Act is evident in its results. In the decade leading up to passage of
180
the Orphan Drug Act the FDA approved only ten orphan drugs.
Conversely, since its enactment nearly 300 orphan drugs have re181
ceived FDA approval. “The response to the Orphan Drug Act is an
example of how favorably the industry responds to increased intellectual property protection that lowers the risk of investing in research,
182
development, and marketing of a new drug.”
New Jersey should consider the Orphan Drug Act not so much
183
as an intellectual property policy template, but rather as an example of the power of properly established policy incentives. That is, if
innovators clearly understand any control the state would have via
standard agency or work-for-hire principles, especially with an intellectual property incentive system working in their favor, then they are
more likely to continue developing stem cell technologies.

177

Id. § 360ee(b)(2)(B). The benefits conferred by the Act apply to treatments
for “any disease or condition [for] which there is no reasonable expectation that the
cost of developing and making available in the United States a drug for such disease
or condition will be recovered from sales in the United States of such drug.” Id.
178
Id. § 360ee(a) (authorizing the Secretary of the Food and Drug Administration
to “make grants to and enter into contracts with public and private entities and individuals” in order to defray the costs of the testing and development of treatments for
rare diseases).
179
Id.; see also Mandy Wilson, Note, Pharmaceutical Patent Protection: More Generic
Favored Legislation May Cause Pioneer Drug Companies to Pull the Plug on Innovation, 90
KY. L.J. 495, 502–04 (2002).
180
Wilson, supra note 179, at 503.
181
Marlene E. Haffner, Adopting Orphan Drugs—Two Dozen Years of Treating Rare
Diseases, 354 NEW ENG. J. MED. 445, 445 (2006). “In the 24 years since this law was
passed, 282 such drugs and biologic products” have been approved. Id.
182
Id. at 503.
183
See supra Part IV.A–B.
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V. CONCLUSION
New Jersey certainly has a proud tradition as a worthy leader and
184
pioneer in the frontier of biomedical research. However, with such
an accolade comes substantial responsibility. Indeed, a foundational
principle of American law is that the optimal way “[t]o promote the
Progress of Science and useful Arts, [is to secure] for limited Times
to Authors and Inventors the exclusive Right to their respective Writ185
ings and Discoveries.”
Thus, there is a recognized government obligation to craft policy that ensures not only appropriate distribution
of ownership rights, but also a fertile marketplace in which public
and private innovation can thrive together.
In undertaking this most integral governmental obligation, New
Jersey would be well-advised to consider—and in some cases, emu186
late—the aforementioned regulatory schemes.
At the very minimum, New Jersey has at its disposal the Edison Innovation R&D
Fund, a regulatory scheme that provides necessary clarity in royalty
187
By adapting this concrete designation of royalty
distribution.
amounts to the stem cell research policy, New Jersey lawmakers would
eliminate the risk of deterring potential innovators who would prefer
to conduct their potentially life-saving research in a state that provides them with adequate notice of how much income they can expect to share. This would not be a particularly onerous or difficult
first step considering the relatively small percentage of royalties that
188
the Edison Fund guarantees to the state.
As the various policies discussed herein demonstrate, however,
the bare minimum is not sufficient. It simply is not enough that New
Jersey’s existing policy vests title in the intellectual property of stem
cell technology to the innovators by merely requiring innovators “to
share with the State of New Jersey a percentage of any income received from the intellectual property that might be developed with
189
The appropriate regulatory regime
the State’s grant support.”
would, for example, qualify this required sharing of royalties with
guarantees that the government will not be able to claim its percent184

See N.J. STAT. ANN. § 26:2Z-1 (West 2006).
U.S. CONST. art. I, § 8, cl. 8.
186
See supra Part IV; see also Entrepreneur Assistance, supra note 124.
187
Entrepreneur Assistance, supra note 124.
188
STATE OF N.J. COMM’N ON SCI. & TECH., EDISON INNOVATION R&D FUND
APPLICATION GUIDELINES, supra note 133, at 6. “1% of net sales resulting from IP developed under the grant—up to the original amount of the grant. 1% of royalty
payments received by the company for licensing IP developed under the grant—up
to 10 times the original amount of the grant.” Id.
189
Stem Cell Research Grant Program, supra note 124.
185
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age merely because it provided some fraction of the funding that may
have led to a major, perhaps even unforeseen, advance several years
later. As such, the NSF Grant Policy, governed by the Bayh-Dole
190
Act, provides particularly useful guidance through a clause requiring that the conception or first application of the technological advance be at least partially attributable to the state’s funds before the
191
government can claim its due percentage of royalties.
At the same time, of course, an ideal policy would recognize the
importance of the government interests as well. For instance, CIRM’s
192
Intellectual Property Policy for Non-Profit Organizations reflects
such interests by guaranteeing free availability of state-funded advances to other California research institutions, despite the fact that
the owner-inventors will maintain ownership of all intellectual prop193
erty. New Jersey’s intellectual property policy on stem cell research
should include a march-in rights provision similar to that provided by
194
CIRM.
That is, if the private innovator—who maintains ownership
of the intellectual property—wastes such ownership by underutilizing
his licensing rights, then the Stem Cell Institute of New Jersey can
step in to ensure public benefit from the medical breakthrough.
Thus, while New Jersey’s policy seems to provide such intellectual
195
property ownership to innovators, a more thorough policy would
protect the public and governmental interests while balancing these
interests with those of the private innovator.
Therefore, a thorough intellectual property policy scheme that
takes into account the interests of all involved parties is an absolutely
essential element to adequate government regulation of state-funded
scientific research. As the Orphan Drug Act illustrated, government
failure to establish the proper environment to develop innovation
196
can have dire consequences.
Thankfully, New Jersey lawmakers
have taken an important first step by recognizing the immeasurable
197
To tap into that potential in the
potential of stem cell research.
most productive and responsible manner, however, New Jersey must
learn from the past, as well as the present treatment of such tech-

190
191
192
193
194
195
196
197

See supra Part IV.B.
See supra note 165–66 and accompanying text.
See supra Part IV.A.
See supra note 147 and accompanying text.
See supra note 149 and accompanying text.
See supra Part II.D.
See supra Part IV.C.
N.J. STAT. ANN. § 26:2Z-1(c) (West 2006).
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nologies by its contemporaries, such as California and the federal
government.
By proclaiming that New Jersey’s status as a biomedical leader
“would be significantly diminished by limitations imposed on stem
198
cell research,” and creating the first state-funded stem cell research
facility in the United States, New Jersey has undoubtedly obligated itself to provide a suitable market for the development of this technology. New Jersey has thus far taken positive steps toward encouraging
199
and funding this groundbreaking research.
However, the state
must recognize the potentially devastating effects of an unsatisfactory
intellectual property policy. Upon making this recognition, New Jersey should take account of existing legislative and regulatory regimes
that are instructive to a government that must adapt its intellectual
200
property policies to cutting-edge technology.
[T]he pitch of the ownership battle will rise proportionally to the
success rate of the research. Thus, the more we achieve the
vaunted promises of stem cell research, the more a crisis will be
precipitated over the ownership of its results. . . . [B]ecause
greater certainty in the investment environment almost always
draws more investment because the risks are more easily calculated . . . we could then get back to the truly important mission at
hand—creating an environment in which the miracles latent in
stem cell research can be realized for the benefit of human201
kind.

Presumably, Thomas Jefferson would not have commissioned
Lewis and Clark without first assuring them that it would be their
names, along with his, that would be remembered for revealing the
bounty of the Louisiana Territory. Likewise, New Jersey cannot afford to withhold such crucial assurances from the scientists on whom
the state will rely to maintain its coveted status as a leader in this burgeoning scientific frontier.

198
199
200
201

Id. § 26:2Z-1(e).
See supra Part II.D.
See supra Part IV.
O’Connor, supra note 96, at 666, 714.

